Professor Richard Day, AM (MBBS, FRACP, MD), is internationally recognized for his research, leadership, and advocacy in support of quality use of medicines. He has been deeply involved in Australia’s National Medicines Policy, culminating in his Chairmanship of the Pharmaceutical Health and Rational Use of Medicines Committee for the Federal Government (1999-2008), and is an active contributor to national resources such as the Australian Medicines Handbook and Therapeutic Guidelines. Professor Day has published over 500 peer-reviewed papers and been cited more than 21,000 times. He was the first non-US President of DIA, and his many awards include Member of the Order of Australia AM (2000) and the AMA Distinguished Service Award (2009).

Dr. Keith Chirgwin joined the Gates Foundation in 2013 as Deputy Director, Regulatory Affairs. He leads regulatory program strategies for the Foundation, working with development partners to ensure the timely and successful development and registration of products . An infectious disease physician with over 25 years of experience across academia and industry, Keith has overseen the regulatory strategy for the successful development and global licensure of several new vaccines and drugs.

Dr. Julie Louise Gerberding, M.D., M.P.H., is the CEO of the Foundation for the NIH where she sets the strategic direction of this nonprofit entity in establishing public private partnerships to accelerate biomedical breakthroughs. This work involves gathering multiple stakeholders such as academia, FDA, industry, and patient organizations. Previously, Julie was the first woman to lead the CDC during the SARS outbreak. Post the CDC Julie served as the Chief Patient Officer and Executive VP of Global Policy, Communications, Sustainabiity and Patient Engagement at Merck.